420,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Foresite Capital Management VI LLC

Foresite Capital Management VI LLC purchased a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 420,000 shares of the company's stock, valued at approximately $11,390,000. Structure Therapeutics accounts for 5.1% of Foresite Capital Management VI LLC's portfolio, making the stock its 7th biggest holding. Foresite Capital Management VI LLC owned about 0.73% of Structure Therapeutics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Boothbay Fund Management LLC grew its stake in shares of Structure Therapeutics by 147.0% during the fourth quarter. Boothbay Fund Management LLC now owns 83,148 shares of the company's stock valued at $2,255,000 after acquiring an additional 49,485 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Silverarc Capital Management LLC increased its holdings in Structure Therapeutics by 116.1% during the 4th quarter. Silverarc Capital Management LLC now owns 152,395 shares of the company's stock worth $4,133,000 after purchasing an additional 81,879 shares during the last quarter. Rock Springs Capital Management LP raised its position in shares of Structure Therapeutics by 1.6% in the 4th quarter. Rock Springs Capital Management LP now owns 1,080,963 shares of the company's stock valued at $29,316,000 after purchasing an additional 17,053 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GPCR. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday. They issued a "buy" rating and a $60.00 target price on the stock. William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $78.63.

Structure Therapeutics Trading Down 0.9 %

NASDAQ GPCR traded down $0.24 during trading hours on Friday, reaching $27.09. The company's stock had a trading volume of 739,761 shares, compared to its average volume of 920,944. The stock has a market cap of $1.55 billion, a PE ratio of -36.61 and a beta of -1.35. The business has a 50-day simple moving average of $20.52 and a 200 day simple moving average of $27.46. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.